<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5581">
  <stage>Registered</stage>
  <submitdate>28/04/2011</submitdate>
  <approvaldate>28/04/2011</approvaldate>
  <nctid>NCT01344863</nctid>
  <trial_identification>
    <studytitle>A Study of Administration of Trastuzumab (Herceptin) by a Single-use Injection Device Versus a Handheld Syringe</studytitle>
    <scientifictitle>A Randomized, Open-label, 2-arm, Parallel Group, Single Dose, Multi-center Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of Trastuzumab Administered Subcutaneously as the Trastuzumab/rHuPH20 Formulation Using a Handheld Syringe or Using the Proprietary Single-use Injection Device (SID)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BO25532</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteer</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - trastuzumab [Herceptin]
Treatment: drugs - trastuzumab [Herceptin]

Experimental: 1 - 

Active Comparator: 2 - 


Treatment: drugs: trastuzumab [Herceptin]
600 mg subcutaneously using a single-use injection device on Day 1

Treatment: drugs: trastuzumab [Herceptin]
600 mg subcutaneously using a handheld syringe on Day 1

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Area under plasma concentration curve of trastuzumab</outcome>
      <timepoint>21 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Maximum observed plasma concentration of trastuzumab</outcome>
      <timepoint>21 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma concentration of trastuzumab</outcome>
      <timepoint>Day 21</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: Incidence of adverse events</outcome>
      <timepoint>21 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy male patients, 18 to 45 years of age, inclusive

          -  No history of hypersensitivity or allergic reactions following drug administration

          -  No history of clinically significant or clinically relevant cardiac condition

          -  No history of previous anticancer treatment

          -  Body mass index (BMI) between 18-32 kg/m2, inclusive</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Positive test result for drugs of abuse

          -  Positive test result for hepatitis B, hepatitis C, or HIV 1 or 2

          -  Systolic blood pressure greater than 140 mmHG or less than 90 mmHG, or diastolic blood
             pressure greater than 90 mmHG or less than 50 mmHG

          -  Clinically significant abnormal laboratory values</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>119</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This randomized, open-label, parallel, 2-arm, multicenter study will compare the
      administration of Herceptin (trastuzumab) with a single-use injection device versus a
      handheld syringe in healthy male volunteers. The volunteers will receive a single dose of 600
      mg Herceptin. The anticipated time of the study is 21 weeks.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01344863</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>